Sol-Gel Technologies Ltd.
SLGL
Rank in Stocks
#16603
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical... Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Share Price
$61.74
Last synced: 2026-11-09
Market Cap
$202.14M
Change (1 day)
1.20%
Change (1 year)
93.66%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sol-Gel Technologies Ltd. (SLGL)
Category
Healthcare
Operating Margin for Sol-Gel Technologies Ltd. (SLGL)
Operating Margin as of November 2026 TTM: -986.96%
According to Sol-Gel Technologies Ltd.'s latest financial reports, its current operating margin (TTM) is -986.96%. At the end of 2025 the company had an operating margin of -38.88%.
Operating Margin history for Sol-Gel Technologies Ltd. from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -986.96% | 2,438.48% |
| 2025 | -38.88% | -62.66% |
| 2024 | -104.13% | -94.48% |
| 2023 | -1,885.78% | 350.78% |
| 2022 | -418.34% | -4,512.87% |
| 2021 | 9.48% | -102.75% |
| 2020 | -344.69% | -404.23% |
| 2019 | 113.30% | -100.44% |
| 2018 | -25,985.27% | 42.93% |
| 2017 | -18,179.89% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.85% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.03% |
BE
|
|
| 29.35% | -100.03% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Sol-Gel Technologies Ltd.'s operating margin
What is Sol-Gel Technologies Ltd.'s operating margin?
Sol-Gel Technologies Ltd.'s operating margin is -986.96%, as of Nov 2026.
What was Sol-Gel Technologies Ltd.'s operating margin in 2025?
In 2025, Sol-Gel Technologies Ltd.'s operating margin was -38.88%, compared with -104.13% in 2024.
How has Sol-Gel Technologies Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Sol-Gel Technologies Ltd.'s operating margin was highest in 2021 (9.48%) and lowest in 2023 (-1,885.78%).
How does Sol-Gel Technologies Ltd.'s operating margin compare with similar companies?
Sol-Gel Technologies Ltd.'s operating margin (-986.96%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.